SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ionis Pharmaceuticals (IONS)
IONS 82.68-1.4%Jan 30 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sds who wrote (1891)4/6/1998 10:59:00 AM
From: Perry  Read Replies (1) of 4676
 
sds thanks for your insight.
Can anyone provide insights on the following concern? It seems that targeting viruses with antisense may be inherantly problematic since viruses tend to mutate (genome, mRNA). Although antisense usually targets a relatively small sequence (~20 bp) on the target mRNA, and thus may not directly be affected my a mutation, this still may pose a problem. It seems to me that targeting oncogenes may be more effective since there are often hot spots that tend to mutate preferentially and thus may prove to be a better target for antisense therapy due to its relative predictability. Any comments?

Thanks,
Perry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News